drugset / Trial / NCT07526350
MTS109 in Patients With Refractory Autoimmune Diseases
NaSingle-groupOpen-labelTreatment
Summary
This is the first-in-human trial of MTS109 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS109 in moderate to severe autoimmune diseases.
Timeline
- Start
- 2026-03-24
- Primary completion
- 2028-04-01
- Completion
- 2029-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MTS109 | Messenger RNA (mRNA) | — | Subcutaneous |